Muramyldipeptide modulates CXCL-8 release of BEAS-2B cells via NOD2

Scandinavian Journal of Immunology

Volumn 68, Issue 3, 2008, Pages 315-322

  Farkas, L ^a,b   Stoelcker, B ^a   Jentsch, N ^a   Heitzer, S ^a   Pfeifer, M ^a,c   Schulz, C ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c Zentrum fur Pneumologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; MURAMYL DIPEPTIDE; RECEPTOR INTERACTING PROTEIN 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRONCHUS MUCOSA; CELL LINE; CELL LINE BEAS 2B; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIUM CELL; GENE INDUCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INNATE IMMUNITY; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; WILD TYPE;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; BRONCHI; CELL LINE, TRANSFORMED; CHEMOKINES, CXC; DRUG SYNERGISM; EPITHELIAL CELLS; HUMANS; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; NOD2 SIGNALING ADAPTOR PROTEIN; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48749123880     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02145.x     Document Type: Article

References (37)

1. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 163: 1304 9.
2. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007 4: 512 21.
3. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996 153: 530 4.
4. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 2001 34: 50 9s.
5. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007 4: 554 64.
6. Quaglietta L, te Velde A, Staiano A, Troncone R, Hommes DW. Functional consequences of NOD2/CARD15 mutations in Crohn disease. J Pediatr Gastroenterol Nutr 2007 44: 529 39.
7. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004 14: 2217 27.
8. Takahashi Y, Isuzugawa K, Murase Y et al. Up-regulation of NOD1 and NOD2 through TLR4 and TNF-alpha in LPS-treated murine macrophages. J Vet Med Sci 2006 68: 471 8.
9. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411: 603 6.
10. Carneiro LA, Travassos LH, Philpott DJ. Innate immune recognition of microbes through Nod1 and Nod2: implications for disease. Microbes Infect 2004 6: 609 16.
11. Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol 2003 24: 652 8.
12. Holler E, Rogler G, Herfarth H et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004 104: 889 94.
13. Brenmoehl J, Herfarth H, Gluck T et al. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med 2007 33: 1541 8.
14. Reddel RR, Ke Y, Gerwin BI et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1988 48: 1904 9.
15. Wolfert MA, Murray TF, Boons GJ, Moore JN. The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan. J Biol Chem 2002 277: 39179 86.
16. Weichart D, Gobom J, Klopfleisch S et al. Analysis of NOD2-mediated proteome response to muramyl dipeptide in HEK293 cells. J Biol Chem 2006 281: 2380 9.
17. Farkas L, Hahn MC, Schmoczer M et al. Expression of CXC chemokine receptors 1 and 2 in human bronchial epithelial cells. Chest 2005 128: 3724 34.
18. Hampe J, Grebe J, Nikolaus S et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002 359: 1661 5.
19. Opitz B, Puschel A, Schmeck B et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004 279: 36426 32.
20. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003 124: 993 1000.
21. Rosenstiel P, Fantini M, Brautigam K et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003 124: 1001 9.
22. Gutierrez O, Pipaon C, Inohara N et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002 277: 41701 5.
23. Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004 31: 358 64.
24. Matsukura S, Stellato C, Georas SN et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 2001 24: 755 61.
25. Bin W, Aksoy MO, Yang Y, Kelsen SG. IL-1{beta} enhances {beta}2-adrenergic receptor expression in human airway epithelial cells by activating PKC. Am J Physiol Lung Cell Mol Physiol 2001 280: L675 9.
26. Schulz C, Farkas L, Wolf K, Kratzel K, Eissner G, Pfeifer M. Differences in LPS-induced activation of bronchial epithelial cells (BEAS-2B) and type II-like pneumocytes (A-549). Scand J Immunol 2002 56: 294 302.
27. Lu C, Wang A, Dorsch M et al. Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity. J Biol Chem 2005 280: 16278 83.
28. Kobayashi K, Inohara N, Hernandez LD et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002 416: 194 9.
29. Hall HT, Wilhelm MT, Saibil SD, Mak TW, Flavell RA, Ohashi PS. RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR responses. Eur J Immunol 2008 38: 64 72.
30. Fritz JH, Girardin SE, Fitting C et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005 35: 2459 70.
31. Davey MP, Martin TM, Planck SR, Lee J, Zamora D, Rosenbaum JT. Human endothelial cells express NOD2/CARD15 and increase IL-6 secretion in response to muramyl dipeptide. Microvasc Res 2006 71: 103 7.
32. Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest 2004 113: 1482 9.
33. Watanabe T, Asano N, Murray PJ et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008 118: 545 59.
34. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004 5: 800 8.
35. Hedl M, Li J, Cho JH, Abraham C. Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A 2007 104: 19440 5.
36. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006 281: 2005 11.
37. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 53: 1658 64.